Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ECE1 | P42892 | 3/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143400 | 1.00 | ECE1 (0.42) | ECE1ACEGPR119CYP3A4KCNH2 | |
| SCHEMBL7137583 | 0.88 | ECE1 (0.37) | ECE1ACEKCNH2 | |
| SCHEMBL7246017 | 0.88 | ECE1 (0.37) | ECE1ACEKCNH2 | |
| SCHEMBL7146330 | 0.88 | ECE1 (0.37) | ECE1 | |
| SCHEMBL7146332 | 0.88 | ECE1 (0.37) | ECE1 | |
| SCHEMBL7146444 | 0.88 | ECE1 (0.39) | ECE1 | |
| SCHEMBL7253112 | 0.88 | ECE1 (0.39) | ECE1 | |
| SCHEMBL7251928 | 0.84 | ECE1 (0.35) | ECE1GPR119KCNH2 | |
| SCHEMBL7137870 | 0.84 | ECE1 (0.35) | ECE1GPR119KCNH2 | |
| SCHEMBL7246798 | 0.84 | ECE1 (0.36) | ECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6660738-B2 | Such as (3R,5S)-1-pyrimidin-2-yl-5-(2,4,5-trifluoro-benzyloxymethyl)-pyrrolidine-3 -thiol trifluoro-acetate useful as inhibitors of metalloproteases for treating diseases associated with vasoconstriction | HOFFMANN-LA ROCHE INC. | 2003-12-09 | — | — | US | disclosed |
| US-20020055632-A1 | Pyrrolidine derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2002-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020055632-A1 | Pyrrolidine derivatives | PREP, PEPD, MMP3 | ECE1 4/4885ACE 85/4885GPR119 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.